NCT03720548View on ClinicalTrials.gov

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

May 14, 2019

Study Completion Date

May 14, 2019

Conditions
Alzheimer Disease
Interventions
DRUG

LY3372993

Administered IV.

DRUG

Placebo

Administered IV.

Trial Locations (11)

27612

Carolina Phase 1 Research (Wake M3), Raleigh

30331

Atlanta Center of Medical Research, Atlanta

32117

Covance Clinical Research Inc, Daytona Beach

32127

Progressive Medical Research, Port Orange

32162

BioClinica Inc, The Villages

32720

Avail Clinical Research LLC, DeLand

32806

BioClinica Inc, Orlando

33009

MD Clinical, Hallandale

33157

IMIC, Inc., Palmetto Bay

84124

PRA Health Sciences, Salt Lake City

90806

Collaborative Neuroscience Network - CNS, Long Beach

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03720548 - A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD) | Biotech Hunter | Biotech Hunter